Pediatric Drug Development by Mathis & Lisa L. Executive Director for Global Regulatory Affairs and Safety GRAAS & Amgen Incorporated & Thousand Oaks & CA

Pediatric Drug Development Second Edition encompasses the new regulatory initiatives across EU US and ROW designed to encourage improved access to safe and effective medicines for children. It includes new developments in biomarkers and surrogate endpoints developmental pharmacology and other novel aspects of pediatric drug development.